| __timestamp | Catalyst Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 504755000 |
| Thursday, January 1, 2015 | 8597010 | 838526000 |
| Friday, January 1, 2016 | 7910260 | 1177697000 |
| Sunday, January 1, 2017 | 7304399 | 1320433000 |
| Monday, January 1, 2018 | 15875961 | 1556200000 |
| Tuesday, January 1, 2019 | 36881187 | 1834800000 |
| Wednesday, January 1, 2020 | 44233754 | 1346000000 |
| Friday, January 1, 2021 | 49628000 | 1824900000 |
| Saturday, January 1, 2022 | 58183000 | 2115900000 |
| Sunday, January 1, 2023 | 133710000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Regeneron Pharmaceuticals, Inc. and Catalyst Pharmaceuticals, Inc. offer a fascinating study in contrasts over the past decade.
From 2014 to 2023, Regeneron consistently reported higher SG&A expenses, peaking at approximately $2.63 billion in 2023. This reflects a strategic investment in growth and market expansion. In contrast, Catalyst Pharmaceuticals maintained a more conservative approach, with expenses rising from $4.47 million in 2014 to $133.71 million in 2023.
While Regeneron's expenses grew by over 400% during this period, Catalyst's expenses increased by nearly 2900%. This stark difference highlights Regeneron's focus on scaling operations, whereas Catalyst's rapid percentage increase suggests a shift from a leaner model to a more aggressive growth strategy.
Selling, General, and Administrative Costs: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Sanofi vs Regeneron Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Regeneron Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated
Cost Management Insights: SG&A Expenses for Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Catalent, Inc. and Catalyst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Catalyst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Catalyst Pharmaceuticals, Inc. or Dynavax Technologies Corporation